Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
DALLAS, Aug. 29, 2017 -- Dougherty’s Pharmacy, Inc. (the “Company”) (OTCQB:MYDP) is pleased to announce that it has been approved to upgrade its common stock from the Pink® Open Market to the OTCQB® Venture Market, effective today, August 29, 2017.
“We are pleased to announce the Company’s upgrade to the OTCQB® Venture Market. We believe this upgrade will assist our current and future shareholders by providing an improved trading market for our Company’s stock and enhance shareholder value,” said President and CFO, Mark Heil.
About Dougherty’s Pharmacy, Inc.
Dougherty’s Pharmacy, Inc. is a retail pharmacy chain focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region of the United States. On June 9, 2017, the Company changed its name from Ascendant Solutions, Inc. to Dougherty’s Pharmacy, Inc. to better reflect the corporate vision and operating structure. Dougherty’s currently has approximately $48 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Dougherty’s at OTCMarkets.com or at www.doughertys.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Securities Act of 1933, the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's current expectations, projections, estimates and assumptions. These forward-looking statements may be identified by words such as "expects," "believes," "anticipates" and similar expressions. Forward-looking statements involve risks and uncertainties that may cause future results to differ materially from those suggested by the forward-looking statements. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.
Contacts: Mark S. Heil President and CFO 972-250-0945 Geralyn DeBusk or Tom Carey Halliburton Investor Relations 972-458-8000
